This inventor holds 1 USPTO granted patent. Top assignee: The University of British Columbia. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: Gleave Martin - Innovator in Antisense Therapy for Tumors
Introduction
Gleave Martin is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of cancer treatment, particularly through his innovative work on antisense therapy for hormone-regulated tumors. His research focuses on developing methods to combat tumors that are influenced by hormonal factors, such as breast and prostate cancers.
Latest Patents
Gleave Martin holds a patent for a method of treating hormone-regulated tumors. This patent, titled "Antisense therapy for hormone-regulated tumors," describes a technique that involves administering an antisense oligodeoxynucleotide (ODN) that is complementary to a portion of the gene encoding IGFBP-5. The administration of this ODN has been shown to reduce the proliferation of tumor cells and delay the progression to androgen independence in prostate cancer. The specific antisense ODNs suitable for this method include GACCACGCTGATCACCAT (Seq. ID. No. 1), CGCCGTGAGCAACACCAT (Seq. ID. No. 3), and AGGTCATGCACCAGCCGC (Seq. ID No. 4).
Career Highlights
Gleave Martin is affiliated with the University of British Columbia, where he conducts his research and develops his innovative therapies. His work has garnered attention for its potential to improve treatment outcomes for patients suffering from hormone-regulated tumors. With 1 patent to his name, Martin continues to push the boundaries of cancer research.
Collaborations
Gleave Martin collaborates with Hideaki Miyake, contributing to the advancement of their shared research interests in cancer therapies. Their partnership exemplifies the importance of teamwork in scientific innovation.
Conclusion
Gleave Martin's contributions to the field of cancer treatment through his antisense therapy patent highlight his role as an innovator in medical research. His work has the potential to significantly impact the lives of patients with hormone-regulated tumors.